Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 26 to 50 of 373

TitleTypeExpected publication date
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attackDiagnostics guidance
Harmful gambling: identification, assessment and managementNICE guideline
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Technology appraisal guidance
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]Technology appraisal guidance
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Technology appraisal guidance
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Technology appraisal guidance
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]Technology appraisal guidance
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidance
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidance
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Technology appraisal guidance
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]Technology appraisal guidance
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]Technology appraisal guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]Technology appraisal guidance
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessmentHealth technology evaluation
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Technology appraisal guidance
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Technology appraisal guidance
Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]Technology appraisal guidance
Heart failure algorithms for remote monitoring in people with cardiac implantable electronic deviceDiagnostics guidance
Adrenal insufficiency: identification and managementNICE guideline
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]Technology appraisal guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidance
Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndromeDiagnostics guidance
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]Technology appraisal guidance
Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All